Summit Therapeutics PLC (SMMT.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|60||2013||Non-Executive Chairman of the Board|
|59||2012||Chief Executive Officer, Executive Director|
|42||2014||Chief Financial Officer|
|2017||Chief Operating Officer, President - Research and Development|
|63||2015||Chief Medical Officer|
- BRIEF-Summit Therapeutics Says Muscle Damage Reduced After Treatment With Ezutromid
- BRIEF-Summit Therapeutics enters exclusive licence agreement with Eurofarma Laboratórios
- BRIEF-Summit highlights DMD biomarker phase 2 clinical trial data in presentations at 22nd WMS Congress
- BRIEF-Summit Therapeutics announces pricing of public offering $12.00 per ADS
- BRIEF-Summit Therapeutics announces proposed public offering of $15 mln of American Depositary shares